Octreotate Lu-177 DOTA Tyr-3 - Advanced Accelerator Applications

Drug Profile

Octreotate Lu-177 DOTA Tyr-3 - Advanced Accelerator Applications

Alternative Names: 177Lu-[DOTA0,Tyr3]octreotate; 177Lu-DOTA0-Tyr3-Octreotate; 177Lu-DOTATATE; 177Lu-labelled somatostatin analog peptide; [Lu-177]-Dota-Tyr3-Octreotate; [Lu-177]-DOTATATE; Lu-DOTATATE; Lutate; Lutathera; Lutetium (177Lu) oxodotreotide; Lutetium Lu 177 dotatate

Latest Information Update: 10 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioSynthema
  • Developer Advanced Accelerator Applications; Centre Hospitalier Universitaire de Quebec; FUJIFILM Pharma; Georgetown University Medical Center; National Cancer Institute (USA)
  • Class Antineoplastics; Peptides; Radiopharmaceuticals
  • Mechanism of Action Somatostatin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Neuroendocrine tumours
  • Phase II Pheochromocytoma
  • Phase I/II Small cell lung cancer

Most Recent Events

  • 20 Nov 2017 Phase-I/II clinical trials in Small cell lung cancer (Combination therapy, Inoperable/Unresectable, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT03325816)
  • 29 Sep 2017 Registered for Neuroendocrine tumours (Inoperable/Unresectable, Metastatic disease) in Norway, Iceland, Liechtenstein, European Union (IM)
  • 29 Sep 2017 Updated efficacy data from a phase III NETTER-1 trial in Neuroendocrine tumours released by Advanced Accelerator Applications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top